Antagonistic effects of styrylpyrone derivative (SPD) on 7,12-dimethylbenzanthracene-induced rat mammary tumors

In Vivo

Volumn 12, Issue 4, 1998, Pages 403-410

  Hawariah, Azimahtol ^a   Stanslas, Johnson ^a  

^a UNIVERSITI KEBANGSAAN MALAYSIA   (Malaysia)

Author keywords

Antitumor activity; Antiuterotrophic; Immature rat uterus; In vivo rat model; Styrylpyrone derivative

Indexed keywords

ANTIESTROGEN; DIMETHYLBENZ[A]ANTHRACENE; ETHAMOXYTRIPHETOL; PYRONE DERIVATIVE; TAMOXIFEN;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST TUMOR; CONTROLLED STUDY; FEMALE; NEWBORN; NONHUMAN; RAT; UTERUS WEIGHT;

EID: 0031857587     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Azimahtol HLP, Munawers M and Din LB: Antifertility effects of SPD: a styrylpyrone isolated from Goniothalamus tapis miqo. Asia Pacific J Pharmacology 9: 273-277, 1994.
2. Maudelonde T, Romieu G, Ulmann A, et al: First clinical trial on use of antiprogestin RU 486 in advanced breast cancer. In. Klijn, JGM, et al (Ed.). Hormonal .Manipulation of Cancer: Peptides, Growth factors and New (Anti) Steroidal Agents: 39-45. New York, Raven Press, 1987.
3. Mouridsen HT and Parideans R: Advanced breast cancer-new approaches to treatment: workshop report. Eur J Cancer Clin Oncol 24: 99-105, 1988.
4. Welsch CW: Host factors affecting the growth of carcinogen-induced rat mammary carcinomas a review and tribute to Charles Brenton Huggins. Cancer Res 45: 3415-3443, 1985.
5. Furr BJA and Jordan VC: The pharmacology and clinical uses of tamoxifen. Pharmac Ther 25: 127-205, 1984.
6. Wakeling AE: Pharmacology of antioestrogens. In: Pharmacology and Clinical Uses Of Inhibitors Of Hormone Secretion And Action (Furr, B.J.A. and Wakeling, A.E, eds).London, Bailliere-Tindal, 1986, pp 1-9.
7. Harper MJK and Walpole AL: Contrasting endocrine activities of cis and trans: isomers in a series of substituted triphenylethylenes. Nature 212: 87-88, 1966.
8. Harper MJK and Walpole AL: A new derivative of kiphenylethylene: effect on implantation and mode of actions in rats. J Reprod Fert 13: 101-119, 1967.
9. Campen CA, Jordan VC and Gorski J: Opposing biological actions of antiestrogens in vitro and in vivo: induction of progesterone receptor in the rat and mouse uterus. Endocrinology 116: 2327-2336, 1985.
10. Rochefort H, Borgna LJ and Evans E: Cellular and molecular mechanism of action of antiestrogens. J Steroid Biochem 19: 69-74, 1983.
11. Wakeling AE: Comparative studies on the effect of steroidal and nonsteroidal oestrogen antagonist on the proliferation of human breast cancer cells. J Steroid Biochem 34: 183-191, 1989.
12. Jordan VC and Murphy CS: Endocrine pharmacology of antiestrogens as an antitumor agent. Endocrine Rev 11(4): 578-610, 1990.
13. Wakeling AEand Bowler J. ICI 182, 180. A new antioestrogen with clinical potential. J Steroid Biochem Molec Biol 43(1-3): 173-177, 1992.
14. Di Salle E, Izaccheo T and Ornatti G: Antiestrogenic and antitumor properties of the new triphenylethylene derivative toremifene in the rat. J Steroid Biochem 36(3): 203-206, 1990.
15. Azimahtol HLP, Stanslas J, and Laily D: Antiprogesterone and antiestrogenic effects of SPD on estrogen target tissues. 7th Asian Symposium on Medicinal Plants, Species and other Natural Products (ASOMPS VII). MP. 17 (Abs.), 1992.
16. Wakeling AE and Valcaccia B 1983: Antioestrogenic and antitumor activities of a series of non-steroidal antioestrogens. J Endocr 99: 455-464, 1983.
17. Lyman SD and Jordan VC: Possible mechanisms for the agonist actions of tamoxifen and the antagonist actions of MER-25 (ethamoxytriphetol) in the mouse uterus. Biochem Pharmacol 34: 2795-2803, 1985.
18. Wakeling AE and Bowler J: Novel antioestrogens without partial agonist activity. J Steroid Biochem 30: 645-651, 1988.
19. Chamness GC, Bannayan GA, Landry L.a. Jr, Sheridan PJ and McGuire WS: Abnormal reproductive tract development in rats after neonatally administered antiestrogens (tamoxifen). Biol Reprod 21: 1087-1090, 1979.
20. Jordan VC: Long term adjuvant tamoxifen therapy for breast cancer: the prelude to prevention. Cancer Treatment Rev 17: 15-36, 1990.
21. Wakeling AE and Bowler J: Biology and mode of action of pure antioestrogens. J Steroid Biochem 31: 141-146, 1988.
22. Wakeling AE, O' Connor MO and Newboult E: Comparison of the biological effects of tamoxifen and a new antiestrogen (LY 117018) on the immature rat uterus. J Endocr 99: 447-453, 1983.
23. Cole MP, Jones CTA and Todd IDH: A new antiestrogenic agent in late breast cancer. An early clinical appraisal of ICI 46,474. Br J Cancer 25: 270-275, 1971.
24. King JP, De Sombre ER, Jensen EV and 10 Mouridsen, HT and Parideans R: Advanced breast cancer-new approaches to treatment: workshop report. Eur J Cancer Clin Oncol 24: 99-105, 1985.
25. Greene GL: Comparison of immunocytochemical and steroid binding assays for estrogen receptor in human breast tumors. Cancer Res 45: 293-304, 1985.
26. Ward HWC: Antioestrogenic therapy for breast cancer: a trial of Tam at two dose levels. Brit Med J 1: 13-18, 1973.
27. Jordan VC and Jaspan T: Tam as an anti-tumour agent. Oestrogen binding as a predictive test for tumour response. J Endocr 68: 453-458, 1976.
28. Schneider MR, Michna H, Nishino Y and El-Etreby MF: Antitumor activity and mechanism of action of different antiprogestins in experimental breast cancer models. J Steroid Biochem Molec Biol 37: 783-789, 1990.
29. Bradley CJ, Kledzik GS and Meites J: Prolactin and estrogen dependency of rat mammary cancers at early and late stages of development. Cancer Res 36: 319-324, 1976.
30. Hansel W and Siefard KH: Physiological characterization on gonadotrophins. Dim. Cole, H.H, and Cupps, P.T. (Ed) Reproduction In Domestic Animal 1: 17-45. Academic Press, 1967.
31. Pourquier H: Adjuvant chemotherapy of breast cancer: Is it a direct cytotoxic or has it an indirect hormone effect? Int J Radiat Oncol Biol Phys 4: 917-919, 1978.